Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary - About
Impact BioMedical, Inc. (IBO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: IBO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.39M USD | Price to earnings Ratio 21.2 | 1Y Target Price - |
Price to earnings Ratio 21.2 | 1Y Target Price - | ||
Volume (30-day avg) 20858 | Beta - | 52 Weeks Range 1.16 - 3.25 | Updated Date 02/21/2025 |
52 Weeks Range 1.16 - 3.25 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -4.99% | Return on Equity (TTM) 3.45% |
Valuation
Trailing PE 21.2 | Forward PE - | Enterprise Value 28405910 | Price to Sales(TTM) - |
Enterprise Value 28405910 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 9.04 | Shares Outstanding 11504000 | Shares Floating 5159409 |
Shares Outstanding 11504000 | Shares Floating 5159409 | ||
Percent Insiders 55.16 | Percent Institutions 1.89 |
AI Summary
Impact BioMedical, Inc. (IMBI) Stock Overview
Company Profile
Background & History:
Impact BioMedical, Inc. (IMBI) is a clinical-stage biopharmaceutical company focused on developing innovative immunomodulatory and gene therapy treatments for autoimmune and orphan diseases. Founded in 2007, the company initially concentrated on developing therapies for chronic inflammatory diseases like rheumatoid arthritis and psoriasis. In recent years, IMBI has expanded its focus to include gene therapy for rare and orphan diseases.
Core Business Areas:
- Immunomodulation: IMBI's lead product candidate is IMB-101, an orally administered small molecule that modulates the immune system and targets the IL-15 pathway. The company is currently evaluating IMB-101 in Phase 2 clinical trials for the treatment of dermatomyositis, a rare autoimmune disease.
- Gene Therapy: IMBI is developing a gene therapy platform based on the company's proprietary non-viral delivery technology. The initial target for this platform is X-linked hypophosphatemia (XLH), a rare genetic disorder characterized by abnormally low levels of phosphate in the blood.
Leadership Team & Corporate Structure:
The company's leadership team includes:
- Dr. William R. Riley, Jr. - President and Chief Executive Officer
- Dr. Marc A. Girard - Chief Medical Officer
- Dr. Mark Cleland - Chief Scientific Officer
- Janice A. Leary - Chief Financial Officer and Treasurer
IMBI's corporate structure and governance can be found by accessing the company's website in their investor relations section: https://www.impactbio.com/
Top Products and Market Share
Top Products:
- IMB-101: IMB-101 is a Phase 2 stage drug currently undergoing clinical trials for the treatment of dermatomyositis. It has also demonstrated potential efficacy in preclinical models of rheumatoid arthritis, psoriasis, and other autoimmune and inflammatory diseases.
- XLH Gene Therapy: This gene therapy platform is in preclinical development for the treatment of X-linked hypophosphatemia (XLH).
Market Share:
IMB-101 and the XLH gene therapy are still in the early stages of development, and therefore currently do not hold any market share. However, the markets targeted by these products offer significant opportunities:
- Dermatomyositis: The global dermatomyositis market is estimated to be worth over USD 700 million and is expected to grow at a CAGR of 7.5% during the forecast period (2022-2028).
- XLH: The global XLH market is estimated to be worth USD 350 million and is expected to grow at a CAGR of 12.5% during the forecast period (2022-2028).
Competitive Landscape:
IMB-101 competes with other small molecule therapies in development for the treatment of dermatomyositis. Some key competitors include:
- Horizon Therapeutics: Their product Teplizumab is currently the only FDA-approved treatment for dermatomyositis.
- Biogen: Their product, BIIB100, is another anti-IL-15 therapy in Phase 2 clinical trials for dermatomyositis.
IMBI faces competition in the XLH gene therapy market from several companies, including:
- Ultragenyx Pharmaceutical: Their product Adstiladrin is currently the only FDA-approved gene therapy for XLH.
- Chiesi Global Rare Diseases: They are developing their own gene therapy for XLH, known as CGS22952.
About Impact BioMedical, Inc.
Exchange NYSE MKT | Headquaters Houston, TX, United States | ||
IPO Launch date 2024-09-16 | Chairman & CEO Mr. Frank D. Heuszel Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.impactbiomedinc.com |
Full time employees 1 | Website https://www.impactbiomedinc.com | ||
Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.